GENERATION BIO CO. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.9 USD | -3.65% |
|
+3.57% | +75.76% |
| Apr. 12 | Transcript : Generation Bio Co. - Special Call | |
| Mar. 07 | Needham Cuts Price Target on Generation Bio to $10 From $14, Maintains Buy Rating | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,292 | 401.9 | 233.5 | 109 | 192.8 | - | - |
| Enterprise Value (EV) 1 | 1,292 | 401.9 | 233.5 | -155.3 | 38.82 | 192.8 | 192.8 |
| P/E ratio | -9.61 x | -3.34 x | -1.67 x | -0.84 x | -2.08 x | -2.23 x | -2.58 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 18.5 x | 34.5 x | 40.4 x | 32.5 x |
| EV / Revenue | - | - | - | -26.3 x | 6.95 x | 40.4 x | 32.5 x |
| EV / EBITDA | -16,627,006 x | - | - | - | - | - | - |
| EV / FCF | -17.1 x | -4.11 x | -2.1 x | 2.58 x | -0.52 x | -2.75 x | - |
| FCF Yield | -5.86% | -24.3% | -47.6% | 38.7% | -191% | -36.3% | - |
| Price to Book | 4.97 x | 1.06 x | 0.81 x | 0.54 x | 1.17 x | 1.3 x | 1.32 x |
| Nbr of stocks (in thousands) | 45,560 | 56,764 | 59,423 | 66,078 | 66,489 | - | - |
| Reference price 2 | 28.35 | 7.080 | 3.930 | 1.650 | 2.900 | 2.900 | 2.900 |
| Announcement Date | 3/18/21 | 2/24/22 | 2/23/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 5.904 | 5.588 | 4.771 | 5.926 |
| EBITDA | - | -77.68 | - | - | - | - | - | - |
| EBIT 1 | - | -81.11 | -119.1 | -141.2 | -138.6 | -101.8 | -102.6 | -108.8 |
| Operating Margin | - | - | - | - | -2,346.93% | -1,822.23% | -2,150.91% | -1,836.26% |
| Earnings before Tax (EBT) 1 | - | -80.52 | -119.2 | -136.6 | -126.6 | -86.87 | -97.67 | -108.3 |
| Net income 1 | -61.32 | -80.52 | -119.2 | -136.6 | -126.6 | -86.9 | -97.65 | -102.6 |
| Net margin | - | - | - | - | -2,144.51% | -1,555.03% | -2,046.68% | -1,730.95% |
| EPS 2 | -7.340 | -2.950 | -2.120 | -2.350 | -1.960 | -1.395 | -1.303 | -1.126 |
| Free Cash Flow 1 | - | -75.66 | -97.78 | -111.2 | -60.14 | -74 | -70 | - |
| FCF margin | - | - | - | - | -1,018.67% | -1,324.16% | -1,467.22% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 5/22/20 | 3/18/21 | 2/24/22 | 2/23/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 0.88 | 2.146 | 2.878 | 1.371 | 1.3 | 1.443 | 1.371 | 0.4333 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -31.66 | -30.95 | -35.34 | -38.48 | -32.67 | -34.69 | -34.87 | -33.92 | -31.36 | -38.42 | -23.9 | -21.3 | -20.7 | -21.1 | -24 |
| Operating Margin | - | - | - | - | - | - | - | -3,854.43% | -1,461.18% | -1,334.99% | -1,742.71% | -1,638.46% | -1,434.65% | -1,538.54% | -5,538.5% |
| Earnings before Tax (EBT) 1 | -31.86 | -30.94 | -35 | -37.93 | -31.31 | -32.4 | -32.09 | -31.07 | -28.27 | -35.19 | -21.57 | -19.13 | -18.8 | -19.37 | -22.1 |
| Net income 1 | -31.86 | -30.94 | -35 | -37.93 | -31.31 | -32.4 | -32.09 | -31.07 | -28.27 | -35.19 | -21.57 | -19.13 | -18.8 | -19.37 | -22.1 |
| Net margin | - | - | - | - | - | - | - | -3,530.23% | -1,317.15% | -1,222.59% | -1,572.57% | -1,471.79% | -1,302.97% | -1,412.15% | -5,100.04% |
| EPS 2 | -0.5600 | -0.5400 | -0.6100 | -0.6600 | -0.5300 | -0.5500 | -0.5300 | -0.4700 | -0.4300 | -0.5300 | -0.4090 | -0.3776 | -0.3465 | -0.3541 | -0.3167 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 2/24/22 | 5/5/22 | 8/4/22 | 11/4/22 | 2/23/23 | 5/10/23 | 8/2/23 | 11/9/23 | 3/6/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | 264 | 154 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -75.7 | -97.8 | -111 | -60.1 | -74 | -70 | - |
| ROE (net income / shareholders' equity) | - | -95.1% | -36.7% | -41.1% | -52.1% | -37.9% | -31.5% | -18.1% |
| ROA (Net income/ Total Assets) | - | -47.9% | -30.9% | -32% | -33.7% | -20.3% | -20% | -13.8% |
| Assets 1 | - | 168.1 | 385.5 | 426.5 | 375.5 | 428 | 488.1 | 742.5 |
| Book Value Per Share 2 | - | 5.710 | 6.700 | 4.860 | 3.070 | 2.480 | 2.230 | 2.190 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 5.52 | 5.96 | 8.8 | 7.4 | 4.85 | 4.62 | 3.46 |
| Capex / Sales | - | - | - | - | 125.29% | 86.86% | 96.93% | 58.41% |
| Announcement Date | 5/22/20 | 3/18/21 | 2/24/22 | 2/23/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.9
USD
Average target price
7.5
USD
Spread / Average Target
+158.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +75.76% | 193M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- GBIO Stock
- Financials Generation Bio Co.
